VEGFA and metastatic colorectal cancer: The primary aim of this multicenter trial was to evaluate the efficacy, safety and survival outcomes of perioperative chemotherapy with XELOX combined with the anti-VEGF targeted agent bevacizumab in patients with potentially curable metastatic colorectal cancer (mCRC).